world
European Commission Opens Antitrust Probe Into Sanofi Flu Vaccine Marketing; Company Says It Complied With Rules
The European Commission opened an antitrust investigation on Friday into whether Sanofi breached EU competition rules in a flu vaccine marketing campaign. The probe focuses on efforts to promote Efluelda while disparaging a rival product in France and Germany.
thenextweb.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The European Commission opened an antitrust investigation on Friday into whether Sanofi breached EU competition rules in a flu vaccine marketing campaign. The probe focuses on efforts to promote the company's Efluelda vaccine while disparaging CSL Seqirus's Fluad product, primarily among healthcare professionals in France and Germany.
Sanofi holds a dominant position in the flu vaccine markets of both countries.
Efluelda is designed to provide greater protection for people over 60. The opening of the investigation follows unannounced raids on Sanofi offices in September 2025, CNBC reported. Sanofi stated it is confident it acted in full compliance with all applicable laws and regulations, including competition rules.
A company spokeswoman called the inquiry a procedural step that does not prejudge the outcome and said Sanofi remains committed to fair competition and to maintaining patient access to innovative vaccines. If anticompetitive practices are confirmed, the European Commission could impose a fine on Sanofi for abuse of a dominant position.
